The Body PRO Covers: The 39th Annual Meeting of the Infectious Diseases Society of America

HIV/AIDS: Antiretroviral Therapy (Poster Session 87)

October 27, 2001

  • Clinical Experience of Amprenavir (APV) Following Nelfinavir (NFV) Use (Poster 694)
    Authored by Stephen L. Becker, Pacific Horizon Medical Group, San Francisco, CA; Douglas T. Dieterich, Liberty Medical Group, New York, NY; Gregory P. Fusco, GlaxoSmithKline, Research Triangle Park, NC

This is a study from the CHORUS database with which I was involved. It looked at patients in the database who were switched from nelfinavir (NLF) to amprenavir or amprenavir/ritonavir (APV/RTV) regimens. The real-life question that this study answers is, "is there cross-resistance between nelfinavir and amprenavir?"

The answer gleaned from this data is that there is apparently no cross-resistance between nelfinavir and amprenavir. This clinical data supports the genotypic and phenotypic data that amprenavir salvage should work in nelfinavir-experienced patients. Only 17% of patients taking amprenavir for a median of 385 days discontinued due to side effects. This suggests that amprenavir is well tolerated. Other randomized trials addressing this question are in progress, however this is good news, suggesting that there is a good option after nelfinavir failure.

Previous | Next

This article was provided by It is a part of the publication 39th Annual Meeting of the Infectious Diseases Society of America.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.